The study of the state of pharmaceutical care for patients with dementia in Alzheimer’s disease in Ukraine
DOI:
https://doi.org/10.24959/sphhcj.24.316Keywords:
dementia; integrated ABC/VEN analysis; clinical and economic analysis; Alzheimer’s disease; pharmaceutical care of psychoneurological patientsAbstract
Aim. To conduct the study of the state of pharmaceutical care for patients with dementia in Alzheimer’s disease in Ukraine.
Materials and methods. Historical, graphic, systematic, logical, mathematical and statistical research methods were used. The analysis of the structure of drug consumption by cost indicators and the number of drugs according to the INN was carried out using an integrated ABC/VEN-analysis, which was based on the distribution of drugs using the formal and expert approach to assessing their clinical value in the treatment of patients.
Results. According to the data of the VEN-analysis using the formal approach (availability of drugs in the relevant regulatory framework), drugs with V status had the lowest consumption volumes (0.4 %) in contrast to the data we obtained when using an expert approach in the distribution of drugs (33.7 %). It was found that in the VEN-analysis (formal approach) the lion’s share in the structure of consumption accounted for drugs from group N – 80.9 %, and according to the data of the expert distribution of drugs, it was equal to 57.7 %. According to the integrated ABC/VEN analysis of drug consumption using the formal approach to assessing the pharmacotherapeutic significance of drugs, it was determined that there were no drugs with A/V status in the treatment of patients. The share of drugs with A/N status was 62.3 %. In turn, according to similar studies in which the expert approach was used, drugs with A/V status accounted for 30.5 % of the total consumption, and A/N was 47.1 %. In the case of using the formal approach, only 16 drugs (12.9 %) were assigned to the first category (vitally important, requiring control), and taking into account the opinion of experts on this issue – 23 (18.5 %) drugs. Category III of drugs (unimportant, not requiring control) included 78 (formal approach) and 48 (expert approach) drugs. In the structure of the total consumption, drugs of category I (formal approach in the VEN analysis) accounted for 80.4 %, and using the expert approach – 83.2 %; in category II, similar indicators were 14.7 % and 14.2 %, and in category III – 4.9 % and 2.6 %, respectively.
Conclusions. In the conditions of the inconsistency of the requirements of the national regulatory and legal framework, which regulates the pharmaceutical care with a modern vision of organizing the treatment process of patients with dementia, the issue of strengthening the cooperation between clinical pharmacists and doctors, as well as the active implementation of the results of clinical and economic studies in practical healthcare is relevant.
References
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L, Jack Jr. C. R., Jones R. W. et al. (2016) Alzheimers Res Ther., 8. Available at: https://pubmed.ncbi.nlm.nih.gov/27646601/.
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames D. et al. (2017). Dementia prevention, intervention, and care. Lancet, 390 (10113), 2673–2734.
Barreto, P. S., Demougeot, L., Vellas, B., Rolland, Y. (2017). Exercise training for preventing dementia, mild cognitive impairment, and clinically meaningful cognitive decline: a systematic review and meta-analysis. Journals of Gerontology Series A: Biological Sciences & Medical Sciences, Dec 5. Available at: https://academic.oup.com/biomedgerontology/article/73/11/1504/4690262.
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D. et al. (2016). Dementia prevention, intervention, and care. The prevalence and incidence of dementia due to Alzheimer’s disease: a systematic review and meta-analysis. Can J Neurol Sci., 43 (1), 51-82.
18 Alzheimer’s disease facts and figures: includes a special report on the financial and personal benefits of early diagnosis. Available at: https://www.alz.org/media/HomeOffice/FactsandFigures/facts-and-figures.pdf.
Hebert, L. E., Weuve, J., Scherr, P. A., Evans, D. A. (2013). Alzheimer’s disease in the United States (2010−2050) estimated using the 2010 census. Neurology, 80, 1778-1783.
Passero, M., Zhai, T., Huang, Z. (2023). Investigation of Potential Drug Targets for Cholesterol Regulation to Treat Alzheimer’s Disease. Int J Environ Res Public Health, 20(13), 6217. doi: 10.3390/ijerph20136217.
Li-Kai Huang, Yi-Chun Kuan, Ho-Wei Lin, Chaur-Jong Hu. (2023). Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update. Journal of Biomedical Science, 83. Available at: https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-023-00976-6.
Tatulian, S. A. (2022). Challenges and hopes for Alzheimer’s disease. Drug Discov. Today, 27, 1027–1043. doi: 10.1016/j.drudis.2022.01.016
Bakre, A. T., Chen, R., Khutan, R., Wei, L., Smith, T., Qin, G. et al. (2018). Association between fish consumption and risk of dementia: a new study from China and a systematic literature review and meta-analysis. Public Health Nutrition, 1(10), 1921–1932.
Fish P. V., Steadman D., Bayle E. D., Whiting P. (2019). New approaches for the treatment of Alzheimer’s disease. Bioorganic & Medicinal Chemistry Letters, 29, 2, 125-133.
Ilomaki J., Jokanovic N., CK Tan E., Lönnroos E. (2015). Alcohol consumption, dementia and cognitive decline: an overview of systematic reviews. Current Clinical Pharmacology, 10(3), 204–212.
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. GBD 2019 Dementia Forecasting Collaborators (2022). Lancet Public Health, 7(2), e105–e125. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810394/.
Obsyag rinku preparatIv dlya lIkuvannya hvorobi Altsgeymera syagne 12,9 mlrd dol. USA u 2028 r. (2020). Schotizhnevik “Apteka”, 25 Chervnya 2020. Available at: https://www.apteka.ua/article/552579.
Canady, V. A. (2023). FDA approves new treatment for Alzheimer’s disease. Ment Heal Wkly, 2023. 33(3), 6–7.
Frozza R. L., Lourenco M. V., De Felice F. G. (2018). Challenges for Alzheimer’s Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. Front Neurosci, 12, 37. doi:10.3389/fnins.2018.00037.
Wanleenuwat, P., Iwanowski, P., Kozubski, W. (2019). Alzheimer’s dementia: pathogenesis and impact of cardiovascular risk factors on cognitive decline Postgrad Med., 131(7), 415–422.
Tatulian, S. A. (2022). Challenges and hopes for Alzheimer’s disease. Drug Discov Today, 27(4), 1027-1043. Available at: https://pubmed.ncbi.nlm.nih.gov/35121174/.
Cummings, J., Rabinovici, G., Atri, A., Aisen, P., Apostolova, L., Hendrix, S. et al (2022). Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis., 9(2), 221–230.
Sharo, C., Zhai T., Huang Z. (2024) Investigation of Potential Drug Targets Involved in Inflammation Contributing to Alzheimer’s Disease Progression. Pharmaceuticals (Basel)., Jan 20, No.17(1), 137. doi: 10.3390/ph17010137.
Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J. et al. (2021). A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. Nat Med., 27(7), 1187–1196.
Dunn B, Stein P, Cavazzoni P. (2021). Approval of aducanumab for Alzheimer disease–the FDA’s perspective. JAMA Intern Med., 181(10), 1276–1278.
Oros, M. (2023). Dementsiia: vyklyky, tendentsii ta stratehii u sviti, shcho zminiuietsia. Zdorovia Ukrainy. Nevrolohiia. Psykhiatriia, 2 (65), 18-19. Available at: https://health-ua.com/multimedia/7/3/3/9/4/1688641994.pdf.
Khaustova, O. (2023). Zhyttia z dementsiieiu: mozhlyvosti suchasnoi terapii. Zdorovia Ukrainy. Nevrolohiia. Psykhiatriia. Psykhoterapiia. 2 (65), 30-31. Available at: https://health-ua.com/article/73458-zhittya-zdementcyu-mozhlivost-suchasno-terap.
Khyts, A. R. (2021) Kohnityvni porushennia: rannia diahnostyka ta osoblyvosti likuvannia. Ukrainskyi medychnyi chasopys, 6(146). 2-4. Available at: https://api.umj.com.ua/wp/wp-content/uploads/2021/12/5057.pdf.
Fedotova, M. S., Panfilova, H. L., Tsurikova O. V., Blazhiievska O. M. (2021). Doslidzhennia epidemiolohii dementsii ta khvoroby Altsheimera v Ukrainy. Visnyk farmatsii, 2 (102), 50-58.
Fedotova, M., Panfilova, H., Hala, L. Lebedyn, A. (2022) Evaluation of the state of pharmaceutical supply of patients with dementia with Alzheimer’s disease in Ukraine in accordance with international recommendations. ScienceRise: Pharmaceutical Science, 4 (38), P. 53-61.
Fedotova, M. S., PanfIlova, G. L., Yurchenko, G. M., Palamar, A. O. (2022). Rezultaty kliniko-ekonomichnoho analizu stanu farmatsevtychnoho zabezpechennia patsiientiv z dementsiieiu vnaslidok khvoroby Altsheimera v Ukraini. Sotsialna farmatsiya v ohoroni zdorov’ya, 9 (3).18-29.
Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi), tretynnoi (vysokospetsializovanoi) ta paliatyvnoi medychnoi dopomohy. Dementsiia : nakaz MOZ Ukrainy No. 736 vid 19.07.2016 pro zatverdzhennia. Available at: https://www.dec.gov.ua/wp-content/uploads/2019/11/2016_736_ykpmd_dem.pdf.
Mintun, M. A., Lo, A. C., Duggan, E. C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W. et al. (2021). Donanemab in early Alzheimer’s disease N Engl J Med., 384(18),1691–1704.
Pro vnesennia zmin do Natsionalnoho pereliku osnovnykh likarskykh zasobiv : postanova Kabinetu ministriv Ukrainy vid 23 hrudnia 2021 r. No. 1431. Available at: https://zakon.rada.gov.ua/laws/show/1431-2021-%D0%BF#Text.
Pro zatverdzhennia piatnadtsiatoho vypusku Derzhavnoho formuliara likarskykh zasobiv ta zabezpechennia yoho dostupnosti : nakaz Ministerstva okhorony zdorovia Ukrainy vid 16.06.2023 r. No. 1102. Apteka online. 2023. Available at: https://www.apteka.ua/article/668182.
Mohammed S. A., Workneh B. D. (2020). Critical Analysis of Pharmaceuticals Inventory Management Using the ABC-VEN Matrix in Dessie Referral Hospital, Ethiopia Integrated Pharmacy Research and Practice, 9, 113–125. doi: 10.2147/IPRP.S265438.
Vaz, F. S., Ferreira, A. M., Kulkarni, M. S., Motghare, D. D., Pereira-Antao, I. (2008). A study of drug expenditure at a tertiary care hospital: An ABC-VED analysis. J Health Manag, 10 (1), 119–127. doi: 10.1177/097206340701000107.
B. W. Taddele, et al. (2019). J Young Pharm., 11 (2), 182–185. doi: 10.5530/jyp.2019.11.38.
Deressa, M. B., Beressa, T. B., Jema, A. (2022). Analysis of Pharmaceuticals Inventory Management Using ABC-VEN Matrix Analysis in Selected Health Facilities of West Shewa Zone, Oromia Regional State, Ethiopia Integrated Pharmacy Research and Practice, 11, 47–59. doi: 10.2147/iprp.s354810.
Hazrati, E., Paknejad, B., Azarashk, A., Taheri, M. (2018). ABC and VED Analysis of Imam Reza Educational Hospital Pharmacy. Ann Mil Health Sci Res., 16 (3), e86183. Available at: https://brieflands.com/articles/amhsr-86183.pdf.
Kashif, M., Sivaprakasam, P., Vijendra, P., Waseem, M., Pandurangan, A. K. (2023). A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer’s Disease. Curr Pharm Des., 29(43), 3428-3441. doi: 10.2174/0113816128264355231121064704.
Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M. et al. (2023). Lecanemab in early Alzheimer’s disease. N Engl J Med., 388(1), 9–21.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
